Tempest Therapeutics Inc. announced that Dr. Vance’s appointment to its advisory board. Dr. Vance joins a distinguished advisory board at Tempest comprising experts whose experience spans elucidating new therapeutic pathways, discovering druggable targets and developing drugs to treat cancer patients. The advisory board at Tempest also includes: Toni Choueiri, M.D. Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DCFI) and Professor of Medicine at Harvard Medical School; Benjamin Cravatt, Ph.D. Professor and the Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute; Raymond DuBois, M.D., Ph.D. Dean of the College of Medicine at the Medical University of South Carolina and a Distinguished Professor and Director of the Hollings Cancer Center; Jason Luke, M.D. Director of the UPMC Hillman Cancer Center (HCC) – Cancer Immunotherapeutics Center and an Associate Professor of Medicine at the University of Pittsburgh; Drew Pardoll, M.D. an Abeloff Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at the Johns Hopkins University, School of Medicine, and the Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and Director of the Cancer Immunology Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; Peppi Prasit, Ph.D. previously served as a Director at Tempest Therapeutics and the CEO of Inception Sciences. Dr. Prasit has over 20 years of experience at Merck Frosst Canada and Merck San Diego where he played a pivotal role in the discovery of multiple marketed drugs.